$BDX

Becton Dickinson (BDX) completed the separation of its life sciences unit, marking the end of its recent portfolio optimization. The company received a favorable price for the unit and will now focus on its existing business and conservative capital allocation, according to the report.

Becton, Dickinson and Company (BDX) deployed its next-generation pharmacy automation robot, BD Vmax 160, at Fairview Health Services. The technology aims to enhance pharmacy efficiency and medication access. BDX stock rose 2.8% following the announcement, though it has fallen 5.8% year-to-date. The company has a market cap of $49 billion.

BD (BDX) announced that Fairview Health Services is the first U.S. health system to deploy the BD Vmax 160, an intelligent pharmacy automation robot. Fairview fills about 20,000 prescriptions weekly and uses the robot to manage demand for specialty therapies and biologics. The system offers high-speed automation, inventory management, and cold-chain capabilities, aiming to improve pharmacy efficiency and medication safety.

Becton Dickinson (BDX) faces legal, operational, and reputational pressures due to a $40M verdict against its subsidiary, C.R. Bard, in Bard PowerPort litigation. Analysts project $21.4B revenue and $3.3B earnings by 2029, with margins expanding from 7.3% to 15.6%. The stock has a consensus target of $195.67, implying ~5.6% upside. Investors weigh litigation risks, tariffs, and business separation plans.

Legal Bay LLC announced it is funding plaintiffs in Bard PowerPort and implanted port catheter lawsuits after a $40 million verdict in Divelbliss v. C.R. Bard. The case, part of a multidistrict litigation, alleges defective design causing serious complications. Legal Bay offers pre-settlement funding to qualified plaintiffs. C.R. Bard and its parent company, Becton Dickinson, face nearly 4,000 pending lawsuits as of September 2026.

Four healthcare stocks—JNJ, ABT, MDT, and BDX—raised dividends through two recessions. JNJ (JNJ, $266.60, 1.97% yield) has a 64-year streak and $21B FCF. MDT (MDT, $90.83, 3.16% yield) leads in yield with 49 years of raises. ABT (ABT, $110.10, 2.22% yield) has 54 years of raises. BDX (BDX, $188.67, 2.23% yield) grew FCF 45% YTD. All benefit from inelastic demand for healthcare products.

Jim Cramer recommended Vale (VALE) as an inflation hedge comparable to crypto, citing its commodity exposure and financials. He also backed Apple (AAPL) due to Tim Cook's endorsement of new CEO John Ternus. Cisco (CSCO) reported strong Q4 revenue but faced share price drops due to conservative guidance. Becton Dickinson (BDX) saw a 33% gain since Cramer's prior call.

BD (BDX) announced its STANCE clinical trial for GalaFLEX LITE™ Scaffold in breast revision surgery has treated 274 patients, surpassing a key milestone. The trial, comparing the scaffold to conventional surgery, aims to support a future FDA application for a new breast indication. BD's P4HB technology has over a decade of clinical use in soft tissue support.

Becton, Dickinson and Co. (BD) launched a noninvasive continuous blood pressure monitoring system, the HemoSphere Stream Module. Tim Patz, BD's Worldwide President of Advanced Patient Monitoring, discussed the future of medtech monitoring, emphasizing the shift towards continuous, noninvasive solutions. BD's pipeline is 95% focused on noninvasive, continuous products, with a focus on high-acuity patients and FDA partnerships. The company has developed AI algorithms for early problem identificati

Becton, Dickinson and Company (BDX) completed enrollment for its PREVENT trial evaluating Phasix Mesh for preventing incisional hernias. The trial enrolled 477 patients and could support an FDA submission, expanding BDX's advanced tissue regeneration platform. BDX shares have traded flat year-to-date, with a market cap of $51.69 billion. Management views this as a long-term growth catalyst.